Amantadine

Generic Name
Amantadine
Brand Names
Gocovri, Osmolex
Drug Type
Small Molecule
Chemical Formula
C10H17N
CAS Number
768-94-5
Unique Ingredient Identifier
BF4C9Z1J53
Background

An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps ...

Indication

For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Associated Conditions
Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism
Associated Therapies
-
Clinical Trials
Related News

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson Disease
Interventions
Drug: Amantadine
Drug: placebo
First Posted Date
2012-02-24
Last Posted Date
2021-02-05
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
210
Registration Number
NCT01538329
Locations
🇫🇷

CHU de Strasbourg, Strasbourg, France

🇫🇷

CH Jean Rougier, Cahors, France

🇫🇷

CHU Dupuytren, Limoges, France

and more 15 locations

Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers

Not Applicable
Completed
Conditions
Healthy Metabolism
Interventions
Drug: Amantadine
First Posted Date
2011-11-08
Last Posted Date
2013-07-29
Lead Sponsor
University of Manitoba
Target Recruit Count
20
Registration Number
NCT01467258
Locations
🇨🇦

St. Boniface General Hospital, Winnipeg, Manitoba, Canada

Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
First Posted Date
2011-09-28
Last Posted Date
2012-07-12
Lead Sponsor
Profil Institut für Stoffwechselforschung GmbH
Target Recruit Count
20
Registration Number
NCT01441986
Locations
🇩🇪

Profil Institute for Metabolic Research, Neuss, NRW, Germany

Pilot Study of Maintenance Therapy With Intravenous AMANTADINE

Not Applicable
Conditions
Parkinson Disease
Interventions
Drug: Amantadine
First Posted Date
2010-08-27
Last Posted Date
2010-10-13
Lead Sponsor
Rabin Medical Center
Target Recruit Count
20
Registration Number
NCT01190553

Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

First Posted Date
2010-04-06
Last Posted Date
2010-11-18
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
40
Registration Number
NCT01099059
Locations
🇮🇷

Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Validation of Dyskinesia Rating Scales

Phase 4
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
Drug: Amantadine
First Posted Date
2010-02-19
Last Posted Date
2022-12-29
Lead Sponsor
Rush University Medical Center
Target Recruit Count
68
Registration Number
NCT01071395
Locations
🇺🇸

Oregon Health & Science University (OHSU), Portland, Oregon, United States

🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

University of Alabama-Birmingham (UAB), Birmingham, Alabama, United States

and more 5 locations

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

Phase 3
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: Amantadine
First Posted Date
2009-10-21
Last Posted Date
2011-02-16
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
40
Registration Number
NCT00999505
Locations
🇧🇷

Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil

Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)

Not Applicable
Withdrawn
Conditions
Traumatic Brain Injury
Interventions
Drug: amantadine
First Posted Date
2008-12-02
Last Posted Date
2022-04-27
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT00800514
Locations
🇺🇸

CHS-Behavioral Health Research, Charlotte, North Carolina, United States

Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability

Not Applicable
Completed
Conditions
Traumatic Brain Injury
Irritable Mood
Aggression
Interventions
Drug: Amantadine
First Posted Date
2008-02-29
Last Posted Date
2022-04-25
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
76
Registration Number
NCT00627250

Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Phase 2
Terminated
Conditions
Parkinson Disease
Perioperative Care
Interventions
Drug: Amantadine
First Posted Date
2008-01-24
Last Posted Date
2011-07-26
Lead Sponsor
Rabin Medical Center
Target Recruit Count
20
Registration Number
NCT00600093
Locations
🇮🇱

Rabin Medical Center, Petah Tikva, Israel

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy